



ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

22nd October 2026

To,
Listing Compliance Department
Metropolitan Stock Exchange of India Ltd.
Building A, Unit 205A, 2nd Floor,
Piramal Agastya Corporate Park,
L.B.S Road, Kurla West,
MUMBAI - 400 070

Symbol: AFDIL, Series: BE, ISIN: INE570E01016

Dear Sir,

Sub: Submission of Reconciliation of Share Capital Audit Report pursuant to Regulation 76(1) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th September 2026

With reference to the captioned subject, we are enclosing herewith the Reconciliation of Share Capital Audit Report obtained from Mr. Raghavendra Naveen B.K., Practicing Company Secretary, for the quarter ended 30th September 2026 pursuant to the provisions of Regulation 76(1) of the SEBI (Depositories and Participants) Regulations, 2018 for your kind perusal.

We request you to kindly take the same on your records.

Thanking You,

Yours Faithfully,
For Anglo-French Drugs & Industries Limited

Sriee Aneetha. M
Company Secretary &
Compliance Officer



Encl: a.a.

Registered Office: No.101, First Floor, Orbit Plaza, New Prabhadevi Road, Prabhadevi,
Mumbai – 400025, Maharashtra, India

Head Office: Plot No.4, Phase-II, Peenya Industrial Area, Peenya, Bangalore-560 058

Tel.: 080 – 2315 4770 E-mail : contact@afdil.com Website: www.afdil.com

CIN No: L24230MH1923PLC463682 GST No.: 29AAACA9756E1ZH



RAGHAVENDRA NAVEEN B K
PRACTICING COMPANY SECRETARY

To

Anglo-French Drugs & Industries Limited,
No.101, First Floor, Orbit Plaza,
New Prabhadevi Road,
Prabhadevi, Mumbai - 400025


Dear Sir/Madam,

I have examined the documents, records and papers produced before us by M/s. ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED, Bengaluru (herein after called "the Company") and Demat reports from Registrar and transfer agents M/s. Integrated Registry Management Services Private Limited, Bengaluru in respect of Reconciliation of Share Capital Audit as per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of my information and according to the examination carried out and explanations furnished to me by the Company, I report the following:

RECONCILIATION OF SHARE CAPITAL AUDIT

1	For Quarter Ended	30/09/2026	
2	ISIN	INE570E01016	
3	Face Value	Rs.10/-	
4	Name of the Company	Anglo-French Drugs & Industries Limited	
5	Registered Office Address	No.101, First Floor, Orbit Plaza, New Prabhadevi Road, Prabhadevi, Mumbai - 400025 Maharashtra, India.	
6	Correspondence Address	Anglo-French Drugs & Industries Ltd. Plot No.4, Phase II, Peenya Industrial Area Peenya, Bengaluru- 560058	
7	Telephone & Fax Nos.	080 2315 6757	
8	Email address	compliance@afdil.com	
9	Names of the Stock Exchanges where the company's securities are listed:	Metropolitan Stock Exchange of India Limited, Mumbai	
		Number of shares	% of Total Issued Capital
10	Issued Capital	11,26,882	100.00%
11	Listed Capital (Exchange-wise) (as per company records) a. Metropolitan Stock Exchange of	11,26,882	100.00%

No.17, 2nd Cross, Sachidananda Nagar, Kengeri Upanaga
Bangalore 560060






RAGHAVENDRA NAVEEN B K
PRACTICING COMPANY SECRETARY

	India Limited, Mumbai		
12	Held in dematerialised form in CDSL	90,385	8.03 %
13	Held in dematerialised form in NSDL	9,95,762	88.36%
14	Held in physical form:	40,735	03.61 %
15	Total No. of shares (12+13+14)	11,26,882	100.00%
16	Reasons for difference if any, between (10&11), (10&15), (11&15):	N/A	
17	Certifying the details of changes in share capital during the quarter under consideration as per Table below:		
a	Particulars		Equity Shares
b	No. of shares		NA
c	Applied / Not Applied for listing		NA
d	Listed on Stock Exchanges (Specify Names)		NA
e	Whether intimated to CDSL		NA
f	Whether intimated to NSDL		NA
g	In-principal approval pending for SE (Specify Names)		NA
18	Register of Members is updated (Yes/ No) If not, updated up to which date	YES -	
19	Reference of previous quarter with regards to excess dematerialised shares, if any.	-NIL-	
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	-NA-	
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:		
	Total No. of demat requests	No. of requests	No. of shares Reasons for delay
	Confirmed after 21 Days	-	- -
	Pending for more than 21 days	-	- -
22	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mrs. Sriee Aneetha M Company Secretary and Compliance Officer M. No: A32388 Tel: +91 91641 76183 Email: sriee.aneeta@afdil.com	
23	Name, Address, Tel. & Fax No., Regn. no. of the Auditor	Mr. Raghavendra Naveen B K Practising Company Secretaries No.17, 2nd Cross, Sachidananda Nagar, Kengeri Upanagar, Bangalore 560060	

No.17, 2nd Cross, Sachidananda Nagar, Kengeri Upanagar,
Bangalore 560060






RAGHAVENDRA NAVEEN B K
PRACTICING COMPANY SECRETARY

		M.No.59814 CP No.23728 Tel: +91 9916667966 Email: support@raoandassociates.co.in
24	Appointment of common agency for share registry work.	M/S. Integrated Registry Management Services Private Limited SEBI Regn No: INR0000000544 No. 30, Ramana Residency, 4th Cross, Sampige Road Malleswaram, Bangalore - 560003 Contact: Mr. Harish K - Chief Manager Tel: +91-80-23460815-818 Email: irg@integratedindia.in
25	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	-None-

The information furnished above is hereby certified.


For CS, Raghavendra Naveen BK
Practicing Company Secretary
ACS.No.59814 CP No.23728
Peer Review Certificate no. 6511/2025
UDIN: A059814H001934161

Date:19/10/2026
Place: Bangalore



**No.17, 2nd Cross, Sachidananda Nagar, Kengeri Upanagar,
Bangalore 560060**